OneVentures is a later-stage venture capital firm focused on scaling technology and healthcare companies through growth equity and credit.

OneVentures

Edison Venture Capital is an Australian venture capital firm.  Information about their specific activities is unavailable due to website errors.

Edison Venture Capital

Giant Leap is an impact venture capital firm that invests in companies addressing global problems through technology and innovation. The firm focuses on areas such as climate, health, and social issues, with a commitment to diversity.

Giant Leap

OneVentures | 11,647 followers on LinkedIn. Investing in transformative founders building for the future | OneVentures is a later-stage Venture Capital Firm, focused on scaling Technology and Healthcare companies through growth equity and credit.
 
Since 2010, OneVentures has launched 7 funds, managing over AU$900M. But we do more than invest.

Venture capital with an entrepreneurial, purposeful approach

Dr Michelle Deaker

Venture Capital, Director, Advisor

Anne-Marie Birkill

Partner | Technology Growth Equity | OneVentures

Bevin Shields

Partner - Chief Operating Officer - General Counsel

Matt Sinnamon

Following the success of our earlier equity funds - Fund I, Fund II and Fund V - we’re excited to launch our 1V Growth Fund VII! The fund will make investments of $10M to $30M in transformative tech companies that have demonstrated significant potential and need support accelerating their growth and expansion in global markets. "Fund VII will continue our strategy of partnering closely with a concentrated portfolio of companies to provide operational and strategic guidance to propel them to the next level. We have a successful track record of investing in visionary founders who have used our expertise to grow their companies and have a global impact.” – Dr Michelle Deaker, Founding Partner & Managing Director We are looking forward to continuing to build strong partnerships with founders and supporting Aussie businesses as they drive innovation and change. Read about the launch, link in our comments 👇

From The Australian top 100 innovators to exciting product launches, October was a great month for 1V & our portfolio! Here are the highlights👇 🏆 Dr Michelle Deaker , Daniel Timms ( BiVACOR ) and David Hoey (Vaxxas) were listed in The Australian 's Top 100 Innovators of 2024 ❤️ The BiVACOR Total Artificial Heart was recognised as one of TIME 's 2024 Best Inventions 👩⚕️ Biotech held their national conference in Melbourne, with Sarah Meibusch , Jeannie Joughin PhD, GAICD and LU LI representing 1V. Daniel Timms (BiVACOR) delivered the keynote oration. Sarah chaired an Investor Panel at Ausbioinvest, led the Early-Stage Investment Forum, participated in a trade secrets panel, and delivered a VC101 at the Bridge satellite event 👷🪁 Buildkite introduced the industry’s first Scale-Out Delivery Platform, integrating multiple DevOps tools into a single platform 🎤 Justine Carzino, CFA joined the LUNA venture capital panel with Scott Dommett ( Rampersand ), Michelle Vu ( LaunchVic ), and Adam Milgrom ( Giant Leap ) 💉 🙅♂️ Vaxxas secured a worldwide license from the The National Institutes of Health for an RSV vaccine antigen, advancing toward clinical trials for the first needle-free RSV vaccine 🔉 Shawn Li joined the judging panel for the Enactus Melbourne x Strive Student Health Initiative Global Health Case Competition Finals at the University of Melbourne and spoke about Growth Credit at a Press Play Ventures event on capital pathways 🥼 ImmVirX announced that two patients have been dosed in a Phase 1b combination study for colorectal, gastric, and ovarian cancers 👩⚖️ Dr Michelle Deaker was a Grand Finalist Judge at SXSW Sydney Pitch, alongside Abheek Anand ( Peak XV Partners ), Melanie Silva ( Google ANZ) and Steven Maarbani ( VentureCrowd ) 👨🚀🛰️ Fleet Space Technologies , in partnership with IsoEnergy Ltd. , launched ExoSphere Discovery, an AI-powered mineral exploration tool that integrates multiphysics data and advanced AI models to predict high-probability drill targets

Congratulations to DermR Health on winning the SXSW Sydney Pitch! Stefan Mazy , DermR Health CEO & founder, pitched a MedTech startup on a mission to prevent one billion skin biopsies by combining a non-invasive microneedle patch technology with genomics. The DermR patch can extract skin cells painlessly by collecting just a few cells to conduct pre-screenings, potentially eliminating the need for unnecessary biopsies. Our Founding Partner, Dr Michelle Deaker , had a great time as a Grand Finalist Judge alongside Melanie Silva ( Google ANZ), Steven Maarbani ( VentureCrowd ) and Abheek Anand ( Peak XV Partners ) Good luck, DermR Health , pitching again at SXSW 2025 in Texas. A huge shoutout to all the finalists - Airee Felt , Outread , OVUM. Technology , SpaceDraft , The Laundry Lady , and WaveX: Wave Powered Generators

"The best time to raise capital is when you don't need it" Our Investment Analyst, Shawn Li recently sat down with Pippin Barry from Dexterity Law to discuss growth credit, its role in supporting tech businesses and how it differs from traditional lenders. 🟠 The best time to raise growth credit is when your business has 9-12 months of runway, ensuring better terms and smoother negotiations. 🟠 Our investors look beyond algorithms, focusing on the company's team, traction and business model, to offer more tailored financing. 🟠 We offer more than capital by providing strategic guidance, connections to investors and operational support to fuel growth. Read the full interview 👉 https://lnkd.in/gxswCixn

"It's a long game and we play the long game at UniQuest for #UQ ," says our CEO Dr Dean Moss GAICD RTTP about commercialising university research to solve the problems that affect us all. Check-out the video on The University of Queensland start-up Vaxxas and its revolutionary needle-free vaccine #tech , the high-density microarray patch (HD-MAP). Hear from Vaxxas CTO Angus Forster and Dr Moss on how this exciting Brisbane company, founded by us in 2011, is developing a potentially transformational global health tool. 🔬🧬👏🚫💉 #vaccine #researchcommercialisation #techtransfer #startup #globalhealth

UniQuest

We’re proud to see our Founding and Managing Partner, Dr Michelle Deaker alongside, Dr Daniel Timms, founder of BiVACOR and David Hoey , CEO of Vaxxas , named among The Australian 's 2024 Top 100 Innovators! Congratulations to all the Innovators. Complete list here https://shorturl.at/d0aGV Michelle's recognition highlights her commitment to Australian innovation, which underpins OneVentures' strategy of investing in companies that solve real-world problems. It also celebrates her successful career at OneVentures and her prior achievements as a technology entrepreneur. Daniel Timms was recognised for founding BiVACOR ’s Total Artificial Heart (TAH). ❤️ BiVACOR is a clinical-stage medical device company developing the TAH, the first long-term solution for patients with severe heart failure. ❤️ Designed for patients with end-stage heart failure, the TAH is designed to replace the native heart's function, to provide vital support while they await a transplant. TAH represents a paradigm shift in artificial heart design, using magnetic levitation technology and a single moving part it has the potential to revolutionise the heart failure field. ❤️ BiVACOR is conducting an FDA-approved Early Feasibility Study and have announced two successful in-human implants this year. David Hoey was recognised as president and CEO of Vaxxas. 💉🙅 Vaxxas is developing a needle-free vaccine technology, the high-density microarray patch (HD-MAP). 💉🙅 The Vaxxas patch consists of thousands of very short (0.25mm) vaccine-coated microprojections. When applied to the skin, via a small applicator, the patch efficiently delivers vaccine to the abundant immune cells in the skin's surface. 💉🙅 With 8 major vaccine programs in development and 3 moving into Phase II trials, this year Vaxxas launched their largest Phase I clinical trial, an avian influenza vaccine trial under their first US FDA IND (Investigational New Drug application)in a program supported by the US government department BARDA. Congratulations Dr Michelle Deaker , Daniel Timms and David Hoey – your groundbreaking work is an example of the power of Aussie innovation 👏

Exciting news - we're welcoming Bevin Shields to the OneVentures Partnership! With over 20 years of experience in growth equity, M&A and capital markets, Bevin has joined us to lead our growth equity investments, including our recently launched Fund VII, alongside Dr Michelle Deaker and Nigel Dews. Fund VII is targeting $200 million to support growth technology companies by providing capital and our operational support to boost sales, enhance marketing and drive expansion into new regions. "We're not just investors, we're also operators in terms of our approach and that is pretty unique. So, it's deliberate because at this growth phase, you have to that breadth of experience across a number of key areas" - Bevin Shields His extensive experience will be invaluable in driving success for our portfolio companies and investors. Great to have you on the team, Bevin alongside Nick Gainsley , Sarah Meibusch , Matt Sinnamon , Nigel Dews and Founding Partners Paul Kelly, Anne-Marie Birkill and Dr Michelle Deaker

We’re excited for SXSW Sydney 2024 next week! Here's where you can find us 👀 Our Founding Partner, Dr Michelle Deaker , will be a Grand Finalist Judge at SXSW Sydney Pitch, alongside Wesley Chan ( FPV Ventures ), Melanie Silva ( Google ANZ) and Steven Maarbani ( VentureCrowd ). This year’s theme, ‘What’s Next’, showcases innovative, mission-driven startups from around the world, offering founders a chance to gain recognition, connect with investors and share solutions that could shape the future. 📅 Thursday, 17th October 🕕 3:30pm - 10pm Rhianna Miller is hosting a WinVC breakfast for women in venture capital in collaboration with VC Women Down Under 📅 Wednesday, 16th October 🕕 8:30am - 10am Register here 🎟️ https://lu.ma/xb4zmgiz 👀 see you there!

Exciting news from Buildkite ! They’ve just announced the industry’s first Scale-Out Delivery Platform, combining multiple previous DevOps tools into a single integrated platform 🪁 This new platform simplifies the process for organisations by eliminating the need to install and configure additional tools separately, making it easier to adopt DevOps best practices. Software delivered using Buildkite is in use by more than 1 billion people daily through their customers such as Airbnb , Canva , Elastic , Lyft , PagerDuty , Pinterest , PlanetScale , Shopify , Slack , Tinder , Twilio , Uber and Wayfair . What’s included in the Scale-Out Delivery Platform? 🪁 Buildkite Pipelines: A scalable workflow orchestration engine for flexible, programmable software delivery automation. 🪁 Buildkite Test Engine: A unified platform for distributed, intelligent test execution with real-time insights. 🪁 Buildkite Package Registries: A high-performance asset management service offering rapid indexing and enhanced security. 🪁 Buildkite Mobile Delivery Cloud: A pre-configured cloud environment for mobile app delivery featuring performance-optimized build systems and per-minute pricing. Congrats Keith Pitt and the Buildkite team on the launch! Click the link in the comments for more info 👇

We are incredibly proud of BiVACOR for completing their second in-human implantation of the Total Artificial Heart (TAH) as part of their FDA early feasibility study. A true demonstration of the power of Australian innovation. Congratulations to Daniel Timms, William Cohn and the BiVACOR team 👏

Metric
Company Name	OneVentures	Edison Venture Capital	Giant Leap
Symbol
MSH ID	AU:COM:ONE-VENTURES	AU:COM:EDISONVENTURECAPITAL	AU:COM:GIANTLEAP
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Financial Services & Finance	Financial Services & Finance
Industry	Venture Capital	Venture Capital	Venture Capital
Country	AU	AU	AU
Stage
Employee Count
Website	one-ventures.com.au	edisonventurecapital.com.au	giantleap.com.au
LinkedIn	oneventures-vc		giantleap-vc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic			517
Web Traffic Growth			-0.24
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM

AU:COM:ONE-VENTURES

OneVentures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue